Everest Medicines (1952) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and company overview

• Aims to become a leading integrated biopharma company in China, leveraging both near-term revenue growth and long-term sustainability through in-licensing and proprietary discovery.

• Commercially launched three products and employs about 800 people, mostly in China.

• Built a robust discovery platform and manufacturing facility to support end-to-end drug development.

Commercialization and product pipeline

• Focuses on dual-engine growth: in-house R&D and in-licensing, with a strong commercial platform (AMMS) for innovative pharmaceuticals in China.

• Nefecon, for IgA nephropathy, achieved RMB 1.2–1.4 billion sales guidance for 2024 and is the first non-oncology product to exceed RMB 1 billion in NRDL sales in its first year.

• Velsipity, targeting ulcerative colitis, is approved in Macau and Singapore, with Mainland China approval expected soon and NRDL coverage targeted for 2027.

• Recent in-licensing and CSO deals expand the portfolio into cardiovascular and ICU therapeutics, adding significant incremental revenue.

R&D and innovation focus

• Early discovery pipeline emphasizes mRNA therapeutics and a proprietary BTK inhibitor (EVER001/civorebrutinib) showing promising results in renal diseases.

• EVER001 demonstrated sustained autoantibody and proteinuria reduction, with plans for pivotal studies and basket trials in multiple indications.

• mRNA platform features end-to-end capabilities, with lead programs in in vivo CAR-T and cancer vaccines, aiming for U.S. IND filing in the first half of 2026.